AAAAAA

   
Results: 1-21 |
Results: 21
Molecular markers predictive of response to chemotherapy in gastrointestinal tumors
Authors: Catalano, V Baldelli, AM Giordani, P Cascinu, S
Citation: V. Catalano et al., Molecular markers predictive of response to chemotherapy in gastrointestinal tumors, CR R ONC H, 38(2), 2001, pp. 93-104
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy
Authors: Cascinu, S Graziano, F Valentini, M Catalano, V Giordani, P Staccioli, MP Rossi, C Baldelli, AM Grianti, C Muretto, P Catalano, G
Citation: S. Cascinu et al., Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy, ANN ONCOL, 12(2), 2001, pp. 239-244
Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients
Authors: Cascinu, S Del Ferro, E Ligi, M Staccioli, MP Giordani, P Catalano, V Agostinelli, R Muretto, P Catalano, G
Citation: S. Cascinu et al., Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients, CANCER INV, 19(1), 2001, pp. 8-12
Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors
Authors: Cascinu, S Graziano, F Catalano, V Staccioli, MP Barni, S Giordani, P Rossi, MC Baldelli, AM Muretto, P Valenti, A Catalano, G
Citation: S. Cascinu et al., Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors, CLIN EXP M, 18(8), 2001, pp. 651-655
Gastrointestinal cancer refractory to chemotherapy: A role for octreotide?
Authors: Cascinu, S Catalano, V Giordani, P Baldelli, AM Agostinelli, R Catalano, G
Citation: S. Cascinu et al., Gastrointestinal cancer refractory to chemotherapy: A role for octreotide?, CHEMOTHERA, 47, 2001, pp. 127-133
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
Authors: Cascinu, S Graziano, F Barni, S Labianca, R Comella, G Casaretti, R Frontini, L Catalano, V Baldelli, AM Catalano, G
Citation: S. Cascinu et al., A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer, BR J CANC, 84(4), 2001, pp. 470-474
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
Authors: Cascinu, S Staccioli, MP Gasparini, G Giordani, P Catalano, V Ghiselli, R Rossi, C Baldelli, AM Graziano, F Saba, V Muretto, P Catalano, G
Citation: S. Cascinu et al., Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer, CLIN CANC R, 6(7), 2000, pp. 2803-2807
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients
Authors: Cascinu, S Bichisao, E Amadori, D Silingardi, V Giordani, P Sansoni, E Luppi, G Catalano, V Agostinelli, R Catalano, G
Citation: S. Cascinu et al., High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients, SUPP CARE C, 8(1), 2000, pp. 65-67
Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
Authors: Cascinu, S Catalano, V Aschele, C Barni, S Debernardis, D Gallo, L Bandelloni, R Staccioli, MP Baldelli, AM Brenna, A Valenti, A Muretto, P Catalano, G
Citation: S. Cascinu et al., Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination, ANN ONCOL, 11(8), 2000, pp. 1053-1056
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
Authors: Graziano, F Catalano, V Baldelli, AM Giordani, P Testa, E Lai, V Catalano, G Battelli, N Cascinu, S
Citation: F. Graziano et al., A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer, ANN ONCOL, 11(10), 2000, pp. 1263-1266
A combination of a fixed dose rate infusion of gemcitabine associated to abolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Authors: Cascinu, S Frontini, L Labianca, R Catalano, V Barni, S Graiff, C Picone, G Farinati, F Zonato, S Pessi, MA Curti, C Catalano, G
Citation: S. Cascinu et al., A combination of a fixed dose rate infusion of gemcitabine associated to abolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD), ANN ONCOL, 11(10), 2000, pp. 1309-1311
Effects of calcium and vitamin supplementation on colon cell proliferationin colorectal cancer
Authors: Cascinu, S Ligi, M Del Ferro, E Foglietti, G Cioccolini, P Staccioli, MP Carnevali, A Rocchi, MBL Alessandroni, P Giordani, P Catalano, V Polizzi, V Agostinelli, R Muretto, P Catalano, G
Citation: S. Cascinu et al., Effects of calcium and vitamin supplementation on colon cell proliferationin colorectal cancer, CANCER INV, 18(5), 2000, pp. 411-416
The value of oxaliplatin in combination with continuous infusion +/- bolus5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: A GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial
Authors: Mosconi, S Cascinu, S Zaniboni, A Catalano, V Giordani, P Beretta, GD Martignoni, G Pancera, G Baldelli, AM Poletti, P Curti, C Labianca, R
Citation: S. Mosconi et al., The value of oxaliplatin in combination with continuous infusion +/- bolus5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: A GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial, TUMORI, 86(6), 2000, pp. 465-469
Prognostic value of S-phase fraction in T3N0M0 gastric cancer. Implications for adjuvant chemotherapy
Authors: Cascinu, S Graziano, F Catalano, V Valentini, M Rossi, MC Baldelli, AM Ghiselli, R Saba, V Giordani, P Catalano, G
Citation: S. Cascinu et al., Prognostic value of S-phase fraction in T3N0M0 gastric cancer. Implications for adjuvant chemotherapy, ANTICANC R, 20(5C), 2000, pp. 3839-3842
Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil
Authors: Cascinu, S Aschele, C Barni, S Debernardis, D Baldo, C Tunesi, G Catalano, V Staccioli, MP Brenna, A Muretto, P Catalano, G
Citation: S. Cascinu et al., Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil, CLIN CANC R, 5(8), 1999, pp. 1996-1999
Intensive versus standard chemotherapy in elderly gastric cancer patients:A retrospective analysis
Authors: Cascinu, S Giordani, P Quattrone, A Catalano, V Antognoli, S Piga, A Catalano, G Cellerino, R
Citation: S. Cascinu et al., Intensive versus standard chemotherapy in elderly gastric cancer patients:A retrospective analysis, GI CANCER, 3(2), 1999, pp. 97-101
Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Authors: Cascinu, S Labianca, R Barni, S Frontini, L Ligi, M Del Ferro, E Silva, RR Pancera, G Pessi, MA Giordani, P Agostinelli, R Catalano, V Rocchi, MB Ghiandoni, G Luporini, G Catalano, G
Citation: S. Cascinu et al., Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD), GI CANCER, 3(1), 1999, pp. 79-83
In vitro selection of glycopeptide-resistant variants of Enterococci
Authors: Puntorieri, M Cafiso, V Santagati, M Messina, C Azzarelli, C Catalano, V Bonfiglio, G Giuseppe, N Stefania, S
Citation: M. Puntorieri et al., In vitro selection of glycopeptide-resistant variants of Enterococci, INT J ANT A, 12(4), 1999, pp. 333-339
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
Authors: Cascinu, S Silva, RR Labianca, R Barni, S Mattioli, R Martignoni, G Frontini, L Gasparini, G Catalano, V Baldelli, AM Giuliodori, L Agostinelli, R Catalano, G
Citation: S. Cascinu et al., A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer, ANN ONCOL, 10(8), 1999, pp. 985-987
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Authors: Cascinu, S Gasparini, G Catalano, V Silva, RR Pancera, G Morabito, A Giordani, P Gattuso, D Catalano, G
Citation: S. Cascinu et al., A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD), ANN ONCOL, 10(11), 1999, pp. 1377-1379
Resection-line involvement in gastric cancer patients undergoing curative resections: Implications for clinical management
Authors: Cascinu, S Giordani, P Catalano, V Agostinelli, R Catalano, G
Citation: S. Cascinu et al., Resection-line involvement in gastric cancer patients undergoing curative resections: Implications for clinical management, JPN J CLIN, 29(6), 1999, pp. 291-293
Risultati: 1-21 |